Caribou Biosciences
Develops genome-edited allogeneic CAR-T candidates for blood cancers.
$1.65
After-hours close+0.04 (+2.17%)
At close$1.62(−2.71%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.29 | — | — |
| Aug 2026 | −$0.32 | −$0.24 | +25.9% |
| Aug 2026 | −$0.32 | −$0.24 | +25.9% |
| May 2026 | −$0.33 | −$0.26 | +21.2% |
| Mar 2026 | −$0.33 | −$0.28 | +15.2% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Sep 2021 | |||
| Jul 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.29 | — | — | $2.2M | — | — |
| Aug 13, 2026 | −$0.32 | −$0.24 | +25.9% | $2.3M | $1.5M | −34.2% |
| Aug 12, 2026 | −$0.32 | −$0.24 | +25.9% | $2.3M | $1.5M | −34.2% |
| May 7, 2026 | −$0.33 | −$0.26 | +21.2% | $2.2M | $2.4M | +8.3% |
| Mar 5, 2026 | −$0.33 | −$0.28 | +15.2% | $2.2M | $3.9M | +78.6% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 12, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 10, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 7, 2024 | ||||||
| Mar 11, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 9, 2023 | ||||||
| Mar 9, 2023 | ||||||
| Nov 8, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 9, 2022 | ||||||
| Mar 21, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Sep 2, 2021 | ||||||
| Jul 23, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||